

DAFTAR PUSTAKA

1. WHO. Breast Cancer. World Health Organization. 2024.
2. American Cancer Society. Breast Cancer Facts & Figures 2022-2024. Atlanta: American Cancer Society; 2022.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018 Nov;68(6):394–424.
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May;71(3):209–49.
5. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024 May;74(3):229–63.
6. The Global Cancer Observatory (GLOBOCAN). *Cancer Today: Indonesia*. 2020. 2020;
7. International Agency of Research on Cancer. *Cancer Today 2022*. World Health Organization. 2024.
8. Menteri Kesehatan Republik Indonesia. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara*. 2018.
9. Trisal V. What is cancer recurrence? City of Hope. 2023.
10. Eveline K, Purwanto H, Lestari P. Faktor Klinis dan Histopatologi serta Hubungannya dengan Kekambuhan Pasca-operasi pada Pasien Kanker Payudara di RSUD Dr. Soetomo. *Indonesian Journal of Cancer*. 2017;11(2).
11. National Cancer Institute. Disease Free Survival. NCI Dictionary of Cancer Terms [Internet]. [cited 2024 Jul 14]; Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/disease-free-survival>
12. Lafourcade A, His M, Baglietto L, Boutron-Ruault MC, Dossus L, Rondeau V. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: The French E3N cohort. *BMC Cancer*. 2018 Feb 9;18(1).
13. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. *J Clin Oncol* [Internet]. 1996 Oct [cited 2024 Jun 3];14(10). Available from: <https://pubmed.ncbi.nlm.nih.gov/8874335/>
14. Botteri E, Bagnardi V, Rotmensz N, Gentilini O, Disalvatore D, Bazolli B, et al. Analysis of local regional recurrences in breast cancer after conservative surgery. *Annals of Oncology*. 2009 Oct 15;21(4):723–8.
15. Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. *J Natl Cancer Inst*. 2013 Oct 2;105(19):1504–11.

16. Wangchinda P, Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. *World J Surg Oncol*. 2016 Aug 24;14(1).
17. Singh AS, Bhardwaj BS, Goswani BC. Disease Free Survival in Locally Advanced Breast Cancer: An Analysis of Clinical and Pathological Factors. *Asian Pacific Journal of Cancer Care*. 2022;7(1).
18. Ithimakin S, Luengwatthanakit N, Wongkraisri C. Follow-Up Strategies and Detection of Recurrent Breast Cancer in the Modern Era. *Asian Pacific Journal of Cancer Prevention*. 2023;24(4):1359–66.
19. Ture M, Tokatli F, Kurt I. Using Kaplan-Meier analysis together with decision tree methods (C&RT, CHAID, QUEST, C4.5 and ID3) in determining recurrence-free survival of breast cancer patients. *Expert Syst Appl*. 2009;36(2 PART 1):2017–26.
20. Chandradewi MR, Manuaba IBTW, Adiputra PAT. Faktor Yang Mempengaruhi Rekurensi Pada Pasien Kanker Payudara Pasca Modified Radical Mastectomy di RSUP Prof. Dr. I G.N.G Ngoerah. *Intisari Sains Medis*. 2022 Dec 7;13(3):690–3.
21. Ayuza M, Harahap WA, Rustam R, Nindrea RD. Faktor yang Berpengaruh Terhadap Disease Free Survival dan Overall Survival pada Pasien Kanker Payudara Usia Muda di Kota Padang Tahun 2008 - 2018. *Jurnal Kesehatan Andalas*. 2020;9.
22. Tanggo VVC. Gradasi Hispatologi Sebagai Prediktor Kejadian Kekambuhan pada Kanker Payudara. Surabaya; 2016.
23. Gusmana AI. Analisis Survival Pasien Kanker Payudara pada Wanita di RSUD Raden Mattaher Jambi Tahun 2017-2019. Jambi; 2024.
24. Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: A meta-analysis. *J Cancer Res Clin Oncol*. 2010 Jul;136(7):1007–22.
25. Devita VT, Hellman S, Rosenberg SA, Lippincott W, Publishers W. *Principles and Practice of Oncology*. 11th ed. Philadelphia: Lippincott-Raven; 2001.
26. Ramli M. Update Breast Cancer Management Diagnostic and Treatment. *Majalah Kedokteran Andalas* [Internet]. 2015 Aug;38(1). Available from: <http://jurnalmka.fk.unand.ac.id>
27. Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. *Breast Cancer Res Treat*. 2008 Feb;107(3):309–30.
28. Koca B, Yildirim M, Kuru B. Prognostic Factors Affecting Disease-Free Survival in Triple-Negative Breast Cancer and Impact of Ki-67. *Indian Journal of Surgery*. 2022 Oct 1;84:708–13.
29. Courtney D, Davey MG, Moloney BM, Barry MK, Sweeney K, McLaughlin RP, et al. Breast cancer recurrence: factors impacting occurrence and survival. *Ir J Med Sci*. 2022 Dec 1;191(6):2501–10.
30. Yap RV, Marquez D Lou, De La Serna FM. Young Filipino breast cancer patients have worse survival outcomes. In: *ecancermedicalscience*. ecancer Global Foundation; 2023.

31. Aryandono T. Faktor prognosis kanker payudara operabel di Yogyakarta [Internet]. Yogyakarta; 2006 [cited 2024 Jun 3]. Available from: https://etd.repository.ugm.ac.id/home/detail_pencarian/31570
32. Dahlan MS. Analisis Survival : Dasar-Dasar Teori dan Aplikasi Program Stata. 2nd ed. Jakarta: Sagung Seto; 2014.
33. Rahayuwati L, Rizal IA, Pahria T, Lukman M, Juniarti N. Pendidikan Kesehatan tentang Pencegahan Penyakit Kanker dan Menjaga Kualitas Kesehatan. Media Karya Kesehatan. 2020 May;3(1).
34. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 34 Tahun 2015 Tentang Penanggulangan Kanker Payudara dan Kanker Leher Rahim. 2015.
35. CDC. Breast Cancer Basics. Centers for Disease. 2024.
36. Sinaga CF, Ardayani T. Hubungan Pengetahuan dan Sikap Remaja Putri Tentang Deteksi Dini Kanker Payudara Melalui Periksa Payudara Sendiri Di SMA Pasundan 8 Bandung Tahun 2016. Jurnal Ilmiah Farmasi. 2016 Jun;4(1):16–9.
37. American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society; 2019.
38. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet [Internet]. 2017 Sep;390(10100):1151–210. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673617321529>
39. Mehrgou A, Akouchekian M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med J Islam Repub Iran [Internet]. 2016;30(15):369. Available from: <http://mjiri.iums.ac.ir>
40. Coughlin SS, Smith SA. The Impact of the Natural, Social, Built, and Policy Environments on Breast Cancer. J Environ Health Sci [Internet]. 2015;1(3). Available from: <http://community.cochrane.org/cochrane-reviews>
41. Shodiq MA. Pengaruh Kombinasi Cyclophosphamide - Transferfactor Terhadap Skor Sel T Cd4+ Pada Adenocarsinomamammae Mencit C3H. Thesis. Semarang; 2011.
42. Heuser L, Spratt JS, Polk Jr HC. Growth rates of primary breast cancers. American Society Cancer [Internet]. 1979 [cited 2024 Jul 13];43(5):1888–94. Available from: [https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142\(197905\)43:5%3C1888::AID-CNCR2820430545%3E3.0.CO;2-M](https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(197905)43:5%3C1888::AID-CNCR2820430545%3E3.0.CO;2-M)
43. Fournier D von, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V. Growth rate of 147 mammary carcinomas. American Cancer Society [Internet]. 1980 [cited 2024 Jul 13];45(8):2198–207. Available from: <https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/1097-0142%2819800415%2945%3A8%3C2198%3A%3AAID-CNCR2820450832%3E3.0.CO%3B2-7>

44. Wu J, Liu H, Hu T, Long M, Zhou X, Wang S. The natural history of breast cancer: a chronological analysis of breast cancer progression using data from the SEER database. *Ann Transl Med.* 2022 Mar;10(6):365–365.
45. Dyayadi. Kanker Payudara [Internet]. 2009 [cited 2024 Jul 13]. Available from: digilib.unimus.ac.id/download.php?id=5468
46. Purwanto H, Handojo D, Haryono S, Harahap W. Panduan Penatalaksanaan Kanker Payudara. 2015. 15–21 p.
47. Ashariati A. Manajemen Kanker Payudara Komprehensif. Surabaya; 2019.
48. American Cancer Society. Preventive Surgery to Reduce Breast Cancer Risk. American Cancer Society. 2021.
49. Suryani Y. Kanker Payudara. 1st ed. Padang: PT. Freeline Cipta Granesia; 2020. 25–27 p.
50. Sheng J, Gupta S. Chemotherapy for Breast Cancer. *Breast Cancer.* 2024.
51. NCI. Breast Cancer Treatment (Adult). National Cancer Institute. 2022.
52. Amelia F. Five level of prevention. Makassar; 2022.
53. Pandve, Tukaram Harshal. Changing concept of disease prevention From primordial to quaternary. *Archieve of Medicine and Health Science* [Internet]. 2014 [cited 2024 Sep 1];2(2):254–6. Available from: https://journals.lww.com/armh/fulltext/2014/02020/changing_concept_of_disease_prevention__from.33.aspx
54. A LK, M J Das. Prevention Strategies. In London: Statpearls; 2023 [cited 2024 Sep 1]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK537222/>
55. Sheng J, DePolo J. Type of Breat Cancer. *Breast Cancer.* 2023.
56. Liu D. Breast cancer recurrence: Types of recurrent breast cancer. *Cancer Center.* 2022.
57. Iswanto C, Anastasia N. Hubungan Demografi, Anggota Keluarga dan Situasi dalam Pengambilan Keputusan Pendanaan Pembelian Rumah Tinggal Surabaya. *Jurnal Finesta.* 2013;1(2):124–9.
58. Masrini S G. Faktor Risiko dari Rekurensi Kanker Payudara pada populasi Asia: studi Meta-Analisis [Internet]. Sumatera Utara; 2021 [cited 2024 Jun 3]. Available from: <https://repositori.usu.ac.id/handle/123456789/46549>
59. Kim SW, Chun M, Han S, Jung YS, Choi JH, Kang SY, et al. Young age is associated with increased locoregional recurrence in node-positive breast cancer with luminal subtypes. *Cancer Res Treat.* 2017 Apr 1;49(2):484–93.
60. Kim G, Pastoriza JM, Qin J, Lin J, Karagiannis GS. Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials. *American Cancer Society.* 2022;128(14).
61. Marissa C, van M, Rachet B, Sonke GS, Mauguen A, Rondeau V, et al. Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands. *Cancer Epidemiol.* 2022 Apr 1;77.
62. Bhardwaj P, Brown KA. Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence. Vol. 11, *Frontiers in Oncology.* Frontiers Media S.A.; 2021.

63. Acevedo F, Walbaum B, Muñiz S, Petric M, Martínez R, Guerra C, et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. *Sci Rep*. 2022 Dec 1;12(1).
64. Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M. American joint committee on cancer's staging system for breast cancer: what the radiologist needs to know. *Radiographics*. 2018;38(7):1921–33.
65. Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, et al. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab. *Onkologie(Czech Republic)*. 2014 Oct;36(10):554–8.
66. Cooper GM. *The Cell: A Molecular Approach*. 2nd ed. Sunderland: Sinauer Associates; 2000.
67. L W, MD D. Tumor-related prognostic factors for breast cancer. *CA Cancer J Clin*. 1997;47(1):28–51.
68. Fei F, Messina C, Slaets L, Chakiba C, Cameron D, Bogaerts J, et al. Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. *Eur J Cancer [Internet]*. 2015 [cited 2024 Jul 3];51(3):301–9. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S0959804914011484>
69. Lin HUI, Zhang FAN, Wang L, Zeng DE. Use of clinical nomograms for predicting survival outcomes in young women with breast cancer. *Oncol Lett*. 2019 Feb 1;17(2):1505–16.
70. Qorina S, Wirnsma Arif Harahap, Ricvan Dana Nindrea. Recurrence Prediction Score of the Locally Advance Breast Cancer in West Sumatera Province, Indonesia. *Bioscientia Medicina : Journal of Biomedicine and Translational Research*. 2021 Sep 15;5(9):890–6.
71. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. *The Breast* 21. 2012;21(1):50–7.
72. Ignatov A, Enggenam H, Burger E, Ignatov T. Patterns of breast cancer relapse in accordance to biological subtype. *J Cancer Res Clin Oncol*. 2018;144(7):1347–55.
73. Borunda EO, Nuñez PA, Aguilar LEA, Valles FOG, Valdespino CAR. Subtype of Breast Cancer. In: N H, Mayrovitz, editors. *Breast Cancer*. Brisbane: Exon Publication; 2022.
74. Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, et al. Patterns of recurrence of early breast cancer according to estrogen receptor status: A therapeutic target for a quarter of a century. *Breast Cancer Res Treat*. 2009 Sep;117(2):319–24.
75. Nishimura R, Osako T, Okumura Y, Nakano M, Ohtsuka H, Fujisue M, et al. An evaluation of lymphovascular invasion in relation to biology and

- prognosis according to subtypes in invasive breast cancer. *Oncol Lett*. 2022 Aug 1;24(2).
76. Lee SJ, Go J, Ahn BS, Ahn JH, Kim JY, Park HS, et al. Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes. *Front Oncol*. 2023;13.
 77. Sleightholm R, Neilsen BK, Elkhatib S, Flores L, Dukkipati S, Zhao R, et al. Percentage of Hormone Receptor Positivity in Breast Cancer Provides Prognostic Value: A Single-Institute Study. *J Clin Med Res*. 2021 Jan 1;13(1):9–19.
 78. Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlersen B, Lash TL, et al. The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis. *J Natl Cancer Inst*. 2022 Mar 1;114(3):391–9.
 79. Kuntoro H. Analisis Kelangsungan Hidup [Internet]. 1st ed. Surabaya: Airlangga University Press; 2017 [cited 2024 Jul 1]. Available from: https://books.google.co.id/books?hl=en&lr=&id=yUV7DwAAQBAJ&oi=f%20nd&pg=PA20&dq=buku+analisis+survival&ots=Zeh7SN_q5x&sig=l mzY%20A7TTVhCslQc9EyaA3l94iqs&redir_esc=y#v=onepage&q=buku%20analisis%20survival&f=false
 80. Yanuar F, Wulandari S, Rahmi HG I. Analisis Survival Untuk Parameter Skala Dari Distribusi Weibull Menggunakan MLE Dan Metode Bayesian. *BAREKENG: Jurnal Ilmu Matematika dan Terapan*. 2021 Mar 1;15(1):147–56.
 81. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text [Internet]. 3rd ed. Gail M, Krickeberg S, editors. Vol. 39. USA: Springer Science Business Media; 2012. Available from: <http://www.springer.com/series/2848>
 82. Abdullah S. Analisis Survival : Konsep dan Aplikasi Dengan R [Internet]. 1st ed. Ahmad K, editor. Jakarta Timur: PT Bumi Aksara; 2022 [cited 2024 Jul 1]. Available from: https://books.google.co.id/books?hl=en&lr=&id=qUvHEAAAQBAJ&oi=f%20nd&pg=PP1&dq=analisis+survival+adalah&ots=oIb5OOIPTe&sig=I4 4cj0%20K5JgNuiir0mf66i_0f7Ks&redir_esc=y#v=onepage&q=analisis%20survival%20adalah&f=false
 83. Gayatri. Mengenal Analisis Ketahanan (Survival Analysis). *Jurnal Keperawatan Indonesia*. 2014;9(1):36–40.
 84. Insan F, Debataraja NN, Rizki SW. Analisis Survival Pada Data Tersensor Tipe I Dengan Metode Kaplan Meier. *Buletin Ilmiah Mat Stat dan Terapannya (Bimaster)*. 2022;11(1):19–26.
 85. Amirah A. Konsep Dan Aplikasi Epidemiologi [Internet]. Sleman: CV Budi Utama; 2020 [cited 2024 Jul 1]. Available from: https://books.google.co.id/books?id=fk0PEAAAQBAJ&printsec=frontcover&hl=id&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false
 86. Asih D, Tarno M, Hoyyi A, Rahmawati R, Wilandari Y. Survival Analysis. Semarang: UNDIP Press; 2021.
 87. Suhartini A, Rahmawati R, Statistika D, Sains dan Matematika F. Analisis Kurva Survival Kaplan Meier Menggunakan Uji Log Rank (Studi

- Kasus :Pasien Penyakit Jantung Koroner di RSUD Undata Palu). 2018;7(1):33–42. Available from: <https://ejournal3.undip.ac.id/index.php/gaussian/>
88. Vandenbroucke JP, Pearce N. Incidence rates in dynamic populations. *Int J Epidemiol*. 2012 Oct;41(5):1472–9.
 89. Safarudin, Prihartono, A N, Gautama W. Pengaruh Indeks Massa Tubuh terhadap Disease-Free Survival Lima Tahun Pasien Kanker Payudara di Rumah Sakit Kanker “Dharmais” Jakarta. *ARTIKEL PENELITIAN Indonesian Journal of Cancer*. 2016;10(1).
 90. Chen CC, Tang WH, Wu CC, Lee TL, Tsai IT, Hsuan CF, et al. Pretreatment Circulating Albumin, Platelet, and RDW-SD Associated with Worse Disease-Free Survival in Patients with Breast Cancer. *Breast Cancer: Targets and Therapy*. 2024;16:23–39.
 91. Paramban M, Asokan V, Tintu M, Ajayakumar T. Clinicopathological factors predictive of pathological response and impact on disease-free survival in breast cancer: Analysis from a tertiary cancer centre in South India. *Journal of Radiation and Cancer Research*. 2022;13(2):54.
 92. Yoo H, Cho KR, Song SE, Cho Y, Jung SP, Sung K. Tumor Heterogeneity of Breast Cancer Assessed with Computed Tomography Texture Analysis: Association with Disease-Free Survival and Clinicopathological Prognostic Factor. *Diagnostics*. 2023 Dec 1;13(23).
 93. Hastono SP. Analisis Data Pada Bidang Kesehatan. 1st ed. Depok: Rajawali Pers; 2022.
 94. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. *Cancer*. 1996 Jan 1;77(1):97–103.
 95. Adami HO, Malke B, Holmberg L. The Relation between Survival and Age at Diagnosis in Breast Cancer. *N Engl J Med*. 1986 Aug 28;315(9):559–63.
 96. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, et al. Effects of young age at presentation on survival in breast cancer. Vol. 6, *BMC Cancer*. 2006.
 97. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. *Cancer*. 2007 May 1;109(9):1721–8.
 98. Keegan THM, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. *Breast Cancer Research*. 2012 Mar 27;14(2).
 99. Anders CK, Hsu DS, Broad Water G, Acharya CR, Foekens JA. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. *J Clin Oncol [Internet]*. 2008 [cited 2024 Jun 3];26(20). Available from: <https://pubmed.ncbi.nlm.nih.gov/18612148/>
 100. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated Breast Cancer Mortality in Women Younger than Age 40 Years

- Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease. *J Am Coll Surg*. 2009 Mar;208(3):341–7.
101. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. *JBUON*. 2013;18(2):335–41.
 102. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience. *Annals of Oncology*. 2004;15(6):875–84.
 103. Canadian Cancer Society. Grading Breast Cancer [Internet]. [cited 2024 Dec 15]. Available from: <https://cancer.ca/en/cancer-information/cancer-types/breast/grading>
 104. Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. *Journal of Clinical Oncology*. 2016 Mar 20;34(9):927–35.
 105. Takayuki I, Daniel B, Vicente V, James LM, Kimberly K. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. *Journal of Clinical Oncology* [Internet]. 2012 Mar 1 [cited 2024 Nov 13];30(7). Available from: <https://pubmed.ncbi.nlm.nih.gov/22291085/>
 106. Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. *Journal of Clinical Oncology*. 2013 Jan 10;31(2):203–9.
 107. Gary M, Ph.D, Clark, William L, McGuire. Progesterone Receptors as a Prognostic Factor in Stage II Breast Cancer. *N Engl J Med* [Internet]. 1983 Dec 1 [cited 2024 Nov 13];309(22):1343–7. Available from: <https://www.nejm.org/doi/pdf/10.1056/NEJM198312013092240?download=true>